HCPLive

Drug Reduces Progression to Clinically Definite MS

Friday, April 20 (HealthDay News) --  As part of a Phase 3 trial, Mark Freedman, M.D., from the University of Ottawa in Canada, and colleagues randomly assigned 517 individuals who had a first clinical demyelinating event and brain lesions detected by magnetic resonance imaging (MRI) to a subcutaneous serum-free formulation of IFN β-1a one or three times a week, or placebo. Placebo patients were switched to IFN β-1a three times a week after two years or after a diagnosis of clinically definite MS.

At three years, the researchers found that the probability of developing clinically definite MS was 41.3 percent for placebo patients switched to IFN β-1a, but was significantly lower for those who received IFN β-1a once a week (27.6 percent) or three times a week (27.1 percent). Similar results were found for the probability of a McDonald MS diagnosis, at 86.5, 79.1, and 66.8 percent, respectively.

"While doses three times a week and once a week equally delayed a clinically definite MS diagnosis without MRI measures, there were significantly more benefits in taking the drug three times a week compared with once a week when it came to brain lesion changes and other McDonald criteria for diagnosing MS," Freedman said in a statement.

The study was supported by Merck Serono S.A.

Press Release
More Information

Individuals suspected of having multiple sclerosis are less likely to be diagnosed with clinically definite disease if they soon start treatment with interferon β-1a, according to a study presented at the annual meeting of the American Academy of Neurology, held from April 21 to 28 in New Orleans.




Copyright © 2012 HealthDay. All rights reserved.

Most Popular

Recommended Reading

Natalizumab, a drug typically used to treat multiple sclerosis and Crohn’s disease, has been shown to be effective in treating animal models of HIV.
Stem cell transplants significantly reduce multiple sclerosis disease activity better than mitoxantrone, according to research published in Neurology.
Having a challenging job may help people live longer after developing frontotemporal dementia, according to a small study published online April 22 in Neurology.
Fred Lublin, MD, and Patricia K. Coyle, MD, describe the approval and use of alemtuzumab for patients with multiple sclerosis.
$vAR$